

SUPPLEMENTARY MATERIAL

Effects of acetaminophen exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small-cell lung cancer: a propensity score-matched analysis.

Fabrizio Nelli¹, Antonella Virtuoso¹, Diana Giannarelli², Agnese Fabbri³, Julio Rodrigo Giron Berrios³, Eleonora Marrucci³, Cristina Fiore³, and Enzo Maria Ruggeri³


¹ Department of Oncology and Hematology, Thoracic Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy

² Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

³ Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy


* **Correspondence:** Fabrizio Nelli, MD; Department of Oncology and Hematology, Thoracic Oncology Unit, Central Hospital of Belcolle, Strada Sammartinese snc, 01100 Viterbo, Italy, Phone +390761339055, Fax +390761339039, e-mail: fabrizio.nelli@asl.vt.it, ORCID iD: 0000-0001-8374-1362

Supplementary Figure 1. Progression-free survival depending on clinical benefit outcome



(A) First-line treatment setting and (B) second-line treatment setting: DCB (durable clinical benefit) vs. NCB (no clinical benefit).

Supplementary Figure 2. Overall survival depending on clinical benefit outcome



(A) First-line treatment setting and (B) second-line treatment setting: DCB (durable clinical benefit) vs. NCB (no clinical benefit).